Overview

Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera) Combined with the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).

Status:
RECRUITING

Trial end date:
2029-12-01

Target enrollment:

Participant gender:

Summary

Study in children and adolescents of 177Lu DOTATATE (Lutathera) combined with the PARP inhibitor olaparib for treatment of recurrent or relapsed solid tumours expressing somatostatin receptors (SSTR) (LuPARPed)

Phase:

PHASE2

Details

Lead Sponsor:

Fundacin de investigacin HM

Treatments:

lutetium Lu 177 dotatate
olaparib